Infliximab-linked gut microbiome signatures as candidate treatment response biomarkers in pediatric inflammatory bowel disease: a systematic review
BackgroundInfliximab (IFX) is a chimeric monoclonal antibody against tumor necrosis factor-alpha (TNF-α) that is widely used for induction and maintenance therapy in pediatric inflammatory bowel disease (IBD), yet its effects on the developing intestinal microbiome and treatment response remain uncl...
Gorde:
| Egile Nagusiak: | , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Frontiers Media S.A.
2026-07-01
|
| Saila: | Frontiers in Pharmacology |
| Gaiak: | |
| Sarrera elektronikoa: | https://www.frontiersin.org/articles/10.3389/fphar.2026.1877033/full |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|